Company
Mithra Pharmaceuticals SA
Headquarters: Liège, Belgium
Employees: 300
Market Cap
€14.5 Million
EUR as of July 1, 2024
US$15.5 Million
Mithra Pharmaceuticals SA Categories
Belgium Healthcare Drug Manufacturers—Specialty & GenericBelgium Healthcare Belgium Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Mithra Pharmaceuticals SA has the following listings and related stock indices.
Stock: FSX: 1TM wb_incandescent
Stock: OTC: MITPF wb_incandescent